TriangleAsciminib single agent (NCT07354074)
Asciminib single agent trial for Chronic Myelogenous Leukemia (NCT07354074). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for children aged one to under eighteen with Philadelphia-positive chronic-phase myeloid leukemia. Cohorts cover newly diagnosed disease, resistance or intolerance to previous kinase inhibitors, and T315I-mutated disease. Typical BCR::ABL1 transcripts are required.
The idea: use asciminib to block the BCR::ABL1 enzyme, interrupting leukemia growth signaling. Formulation and dosing depend on the child; tablet strength is not the prescribed dose. Researchers assess molecular response at week 48 and monitor growth, development and safety. Prior stem-cell transplant is excluded.
This phase 2 study plans 50 patients. Novartis sponsors four recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.